These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Clinical applications of antiarrhythmic drugs. Lavenne F; de Jonghe D Acta Cardiol Suppl; 1980; (25):27-42. PubMed ID: 6155012 [No Abstract] [Full Text] [Related]
23. Interactions between implantable cardioverter-defibrillators and class III agents. Movsowitz C; Marchlinski FE Am J Cardiol; 1998 Aug; 82(4A):41I-48I. PubMed ID: 9737653 [TBL] [Abstract][Full Text] [Related]
24. The coming of age of the class III antiarrhythmic principle: retrospective and future trends. Singh BN Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325 [TBL] [Abstract][Full Text] [Related]
25. Early Detection of Symptomatic Paroxysmal Cardiac Arrhythmias by Trans-Telephonic ECG Monitoring: Impact on Diagnosis and Treatment of Atrial Fibrillation. Anczykowski J; Willems S; Hoffmann BA; Meinertz T; Blankenberg S; Patten M J Cardiovasc Electrophysiol; 2016 Sep; 27(9):1032-7. PubMed ID: 27257094 [TBL] [Abstract][Full Text] [Related]
26. Management of ventricular arrhythmias: then and now. Bennett B; Singh S Am J Crit Care; 1992 Nov; 1(3):107-14. PubMed ID: 1307899 [TBL] [Abstract][Full Text] [Related]
29. [Update on arrhythmias and cardiac electrophysiology]. Arenal Maíz A; Castel MA; López Gil M; Merino Llorens JL Rev Esp Cardiol; 2009 Jan; 62 Suppl 1():67-79. PubMed ID: 19174051 [TBL] [Abstract][Full Text] [Related]
30. Sudden death: managing the patient who survives. Pachón M; Almendral J Heart; 2011 Oct; 97(19):1619-25. PubMed ID: 21900587 [No Abstract] [Full Text] [Related]
31. MY APPROACH to early repolarization syndrome. Yan GX Trends Cardiovasc Med; 2016 May; 26(4):393-4. PubMed ID: 26944231 [No Abstract] [Full Text] [Related]
32. The role of class III antiarrhythmic agents in maintaining sinus rhythm. Brachmann J Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519 [TBL] [Abstract][Full Text] [Related]
36. [Therapy of cardiac arrhythmias: when, how and where?]. Wellens HJ; Brugada P Grud Serdechnososudistaia Khir; 1991 Mar; (3):5-14. PubMed ID: 2049197 [TBL] [Abstract][Full Text] [Related]
37. Desired mechanisms of drugs for ventricular arrhythmia: class III antiarrhythmic agents. Lipka LJ; Dizon JM; Reiffel JA Am Heart J; 1995 Sep; 130(3 Pt 1):632-40. PubMed ID: 7661091 [No Abstract] [Full Text] [Related]
38. Update on management of cardiac arrhythmias in acute coronary syndromes. Willich T; Goette A Minerva Cardioangiol; 2015 Apr; 63(2):121-33. PubMed ID: 25612305 [TBL] [Abstract][Full Text] [Related]
39. [Anti-arrhythmia treatment (clinical problems, classification of anti-arrhythmia drugs and personal experience]. Walczak F Kardiol Pol; 1992; 36(2):97-104. PubMed ID: 1583833 [No Abstract] [Full Text] [Related]
40. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Priori SG; Blomström-Lundqvist C; Mazzanti A; Blom N; Borggrefe M; Camm J; Elliott PM; Fitzsimons D; Hatala R; Hindricks G; Kirchhof P; Kjeldsen K; Kuck KH; Hernandez-Madrid A; Nikolaou N; Norekvål TM; Spaulding C; Van Veldhuisen DJ; Europace; 2015 Nov; 17(11):1601-87. PubMed ID: 26318695 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]